Literature DB >> 33585189

Molecular Pathological Markers Correlated With the Recurrence Patterns of Glioma.

Shunnan Ge1, Yingwu Shi1, Gang Zhu1, Songlun Li2, Yaning Cai1, Peigang Ji1, Jinghui Liu1, Wei Guo1, Li Gong3, Miao Lou1, Fuqiang Feng4, Yuan Wang1, Yulong Zhai1, Yan Qu1, Liang Wang1.   

Abstract

PURPOSE: Glioma is one of the most common tumors of the central nervous system, and many patients suffer from recurrence even after standard comprehensive treatment. However, little is known about the molecular markers that predict the recurrence patterns of glioma. This study aimed to demonstrate the correlations between molecular markers and glioma recurrence patterns, which included local/nonlocal recurrence and paraventricular/nonparaventricular recurrence.
METHODS: Immunohistochemical techniques were used to assess the molecular markers of 88 glioma tissues following surgical resection. The recurrence patterns were divided into local recurrence, marginal recurrence, distant recurrence, multirecurrence, and subarachniod recurrence, with the last four recurrence patterns being collectively called nonlocal recurrence. According to whether the recurrence invaded ventricles, the nonlocal recurrence patterns were divided into paraventricular and nonparaventricular recurrence. Then, we compared the different recurrence patterns and their clinical characteristics, focusing on the expression of molecular markers.
RESULTS: More patients in the nonlocal recurrence group received combined radiotherapy and chemotherapy than patients in the local recurrence group (p=0.019). Sex, age, extent of surgery, time to recurrence, tumor location, size, and WHO grade were not different in the defined groups (P>0.05). Recurrent tumor volume and WHO grade were significantly different between the paraventricular and nonparaventricular recurrence groups (p=0.046 and 0.033). The expression of Ki-67, P53, and PCNA in the nonlocal recurrence group was significantly higher than that in the local recurrence group (p=0.015, 0.009, and 0.037), while the expression of S-100 in the nonlocal recurrence group was significantly lower than that in the local recurrence group (p=0.015). Cox regression indicated hazard ratio (HR) for high expression level of PCNA associated with non-local recurrence was 3.43 (95% CI, 1.15, 10.24), and HR for high expression level of MGMT associated with paraventricular recurrence was 2.64 (95% CI, 1.15,6.08).
CONCLUSIONS: Ki-67, P53, PCNA, and MGMT might be important clinical markers for nonlocal recurrence and paraventricular recurrence.
Copyright © 2021 Ge, Shi, Zhu, Li, Cai, Ji, Liu, Guo, Gong, Lou, Feng, Wang, Zhai, Qu and Wang.

Entities:  

Keywords:  O6-Methylguanine DNA methyltransferase; glioma; local recurrence; molecular markers; paraventricular recurrence

Year:  2021        PMID: 33585189      PMCID: PMC7873968          DOI: 10.3389/fonc.2020.565045

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  42 in total

Review 1.  A practical review of prognostic correlations of molecular biomarkers in glioblastoma.

Authors:  Michael Karsy; Jayson A Neil; Jian Guan; Mark A Mahan; Mahan A Mark; Howard Colman; Randy L Jensen
Journal:  Neurosurg Focus       Date:  2015-03       Impact factor: 4.047

Review 2.  Adult Pilocytic Astrocytoma: An Institutional Series and Systematic Literature Review for Extent of Resection and Recurrence.

Authors:  Kamila M Bond; Joshua D Hughes; Amanda L Porter; Josiah Orina; Shanna Fang; Ian F Parney
Journal:  World Neurosurg       Date:  2017-11-24       Impact factor: 2.104

3.  Role of Ki-67 labeling index as an adjunct to the histopathological diagnosis and grading of astrocytomas.

Authors:  Mahathi Thotakura; Neelima Tirumalasetti; Ravi Krishna
Journal:  J Cancer Res Ther       Date:  2014 Jul-Sep       Impact factor: 1.805

4.  Differential expression of S100 calcium-binding proteins characterizes distinct clinical entities in both WHO grade II and III astrocytic tumours.

Authors:  I Camby; F Lefranc; G Titeca; S Neuci; M Fastrez; L Dedecken; B W Schäfer; J Brotchi; C W Heizmann; R Pochet; I Salmon; R Kiss; C Decaestecker
Journal:  Neuropathol Appl Neurobiol       Date:  2000-02       Impact factor: 8.090

5.  The lncRNA UCA1 interacts with miR-182 to modulate glioma proliferation and migration by targeting iASPP.

Authors:  Zongze He; Yujue Wang; Guangfu Huang; Qi Wang; Dongdong Zhao; Longyi Chen
Journal:  Arch Biochem Biophys       Date:  2017-01-28       Impact factor: 4.013

6.  Neurospecific proteins in the serum of patients with brain tumors.

Authors:  N V Lyubimova; M G Toms; E E Popova; Y V Bondarenko; V B Krat; N E Kushlinskii
Journal:  Bull Exp Biol Med       Date:  2011-04       Impact factor: 0.804

Review 7.  Molecular markers in glioma.

Authors:  Kirsten Ludwig; Harley I Kornblum
Journal:  J Neurooncol       Date:  2017-02-23       Impact factor: 4.130

8.  NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.

Authors:  Louis Burt Nabors; Jana Portnow; Mario Ammirati; Joachim Baehring; Henry Brem; Nicholas Butowski; Robert A Fenstermaker; Peter Forsyth; Jona Hattangadi-Gluth; Matthias Holdhoff; Steven Howard; Larry Junck; Thomas Kaley; Priya Kumthekar; Jay S Loeffler; Paul L Moots; Maciej M Mrugala; Seema Nagpal; Manjari Pandey; Ian Parney; Katherine Peters; Vinay K Puduvalli; John Ragsdale; Jason Rockhill; Lisa Rogers; Chad Rusthoven; Nicole Shonka; Dennis C Shrieve; Allen K Sills; Lode J Swinnen; Christina Tsien; Stephanie Weiss; Patrick Yung Wen; Nicole Willmarth; Mary Anne Bergman; Anita Engh
Journal:  J Natl Compr Canc Netw       Date:  2017-11       Impact factor: 11.908

Review 9.  Glioblastoma Multiforme and Adult Neurogenesis in the Ventricular-Subventricular Zone: A Review.

Authors:  Claudia Capdevila; Lucía Rodríguez Vázquez; Joaquín Martí
Journal:  J Cell Physiol       Date:  2017-01-31       Impact factor: 6.384

10.  Recurrence patterns after maximal surgical resection and postoperative radiotherapy in anaplastic gliomas according to the new 2016 WHO classification.

Authors:  Jung Ho Im; Je Beom Hong; Se Hoon Kim; Junjeong Choi; Jong Hee Chang; Jaeho Cho; Chang-Ok Suh
Journal:  Sci Rep       Date:  2018-01-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.